Skip to main content

Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study


BackgroundAndrogen deprivation therapy (ADT) is essential in the treatment of advanced and metastatic prostate cancer. As the correlation between hormone therapy and hypertension remains unclear and prostate cancer is less prevalent in the Asian population, the clinician should focus on not only anticancer therapy but also the side effects of the intervention and quality of life of these patients.ObjectiveThis study aimed to investigate the risk of subsequent hypertension in patients undergoing androgen deprivation therapy for prostate cancer.Setting Data of 10,843 patients with prostate cancer were retrospectively collected from the Longitudinal Health Insurance Database of Taiwan. The institutional review board of Kaohsiung Medical University Hospital approved our study.Method In propensity score matching, 3001 patients with prostate cancer aged ≥ 40 years who underwent androgen deprivation therapy were included in the study cohort (androgen deprivation therapy-ever), and 3001 patients with cancer who did not undergo androgen deprivation therapy were included in the control group (androgen deprivation therapy-never), after adjusting for age and other comorbidities.Main outcome measure The event of new-onset hypertension between the study cohort and control cohort.ResultsDuring the average 5-year follow-up period, the incidence rates of new-onset hypertension were 22.6 and 33.0 per 1000 person-years in the androgen deprivation therapy-never and androgen deprivation therapy-ever cohorts, respectively. The androgen deprivation therapy-ever cohort was found to be 1.78 times more likely to develop new-onset hypertension than was the control group (95% confidence interval [CI], 1.61–1.96; P < 0.001). Moreover, the subgroup of combined androgen blockade had almost doubled the risk of subsequent hypertension (adjusted hazard ratio, 1.93; 95% CI 1.71–2.18; P < 0.001).ConclusionsOur study suggests that men with prostate cancer who underwent androgen deprivation therapy are at risk of developing hypertension in the future.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  Google Scholar 

  2. 2.

    Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581–8.

    CAS  Article  Google Scholar 

  3. 3.

    Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.

    CAS  Article  Google Scholar 

  4. 4.

    Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.

    Article  Google Scholar 

  5. 5.

    Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097–106.

    CAS  Article  Google Scholar 

  6. 6.

    Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–36.

    CAS  Article  Google Scholar 

  7. 7.

    Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.

    Article  Google Scholar 

  8. 8.

    Campbell NR, Lackland DT, Lisheng L, Niebylski ML, Nilsson PM, Zhang XH. Using the Global Burden of Disease study to assist development of nation-specific fact sheets to promote prevention and control of hypertension and reduction in dietary salt: a resource from the World Hypertension League. J Clin Hypertens. (Greenwich Conn). 2015;17(3):165–7.

    Article  Google Scholar 

  9. 9.

    Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171(6 Pt 1):2285–90.

    Article  Google Scholar 

  10. 10.

    Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol. 2012;62(5):757–64.

    CAS  Article  Google Scholar 

  11. 11.

    Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, et al. Low free testosterone and prostate cancer risk: a collaborative analysis of 20 prospective studies. Eur Urol. 2018;74(5):585–94.

    CAS  Article  Google Scholar 

  12. 12.

    Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217(3):R47–71.

    CAS  Article  Google Scholar 

  13. 13.

    Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, et al. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation. 1996;94(10):2614–9.

    CAS  Article  Google Scholar 

  14. 14.

    Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–7.

    CAS  Article  Google Scholar 

  15. 15.

    Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195–201.

    CAS  Article  Google Scholar 

  16. 16.

    Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl. 2009;30(4):410–5.

    CAS  Article  Google Scholar 

  17. 17.

    Oka R, Utsumi T, Endo T, Yano M, Kamijima S, Kamiya N, et al. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Int J Clin Oncol. 2016;21(2):389–96.

    CAS  Article  Google Scholar 

  18. 18.

    Nowicki M, Bryc W, Kokot F. Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. J Endocrinol Investig. 2001;24(1):31–6.

    CAS  Article  Google Scholar 

  19. 19.

    Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71(2):318–22.

    Article  Google Scholar 

  20. 20.

    Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1–7.

    CAS  Article  Google Scholar 

  21. 21.

    Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7.

    CAS  Article  Google Scholar 

  22. 22.

    Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, et al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int. 2011;107(6):929–35.

    Article  Google Scholar 

  23. 23.

    Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:31358.

    CAS  Article  Google Scholar 

  24. 24.

    Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Investig. 2013;36(2):132–9.

    CAS  Article  Google Scholar 

  25. 25.

    Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G, et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension. 2012;59(4):802–10.

    CAS  Article  Google Scholar 

  26. 26.

    Berger SM, Gislason G, Moore LL, Andersson C, Torp-Pedersen C, Denis GV, et al. Associations between metabolic disorders and risk of cancer in Danish men and women–a nationwide cohort study. BMC Cancer. 2016;16:133.

    Article  Google Scholar 

  27. 27.

    Harding JL, Sooriyakumaran M, Anstey KJ, Adams R, Balkau B, Brennan-Olsen S, et al. Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J Hypertens. 2016;34(1):149–55.

    CAS  Article  Google Scholar 

Download references


The authors would like to acknowledge the Department of Internal Medicine and the Statistical Analysis Laboratory in the Department of Medical Research at Kaohsiung Medical University Hospital.


The study was supported by grants from Kaohsiung Medical University Hospital (KMUH-107-7M28).

Author information



Corresponding author

Correspondence to Yung-Chin Lee.

Ethics declarations

Conflicts of interest

There are no conflicts of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wu, YH., Jhan, JH., Ke, HL. et al. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study. Int J Clin Pharm 42, 1433–1439 (2020).

Download citation


  • Androgen-deprivation therapy
  • Combined androgen blockade
  • Hormone therapy
  • Hypertension
  • Prostate cancer